Replimune Group, Inc. (REPL) director option exercise and stock sale

Rhea-AI Filing Summary

Replimune Group, Inc. director reported an option exercise and share sale on 12/09/2025. The director exercised a stock option for 3,169 shares of common stock at an exercise price of $1.75 per share (transaction code M), then sold 3,169 shares of common stock at $10.4 per share the same day (transaction code S). After these transactions, the director reported beneficial ownership of 0 shares of common stock and 0 derivative securities from this option grant.

The disclosure explains that the option was exercised due to the upcoming 01/21/2026 expiration date, and that all 3,169 shares underlying this stock option had vested on 01/21/2016.

Insider Trade Summary

Net Seller: 3,169 shares ($32,958)

Net Sell 3 txns

Insider Dhingra Kapil

Role Director

Sold 3,169 shs ($33K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,169	$0.00	--
Exercise	Common Stock	3,169	$1.75	$6K
Sale	Common Stock	3,169	$10.40	$33K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 3,169 shares (Direct)

Footnotes (1)

1. The reporting person exercised the option due to the upcoming expiration date of the option. All of the shares underlying this stock option vested on January 21, 2016.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhingra Kapil

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M		3,169	A	$1.75(1)	3,169	D
Common Stock	12/09/2025		S		3,169	D	$10.4	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.75	12/09/2025		M			3,169	(2)	01/21/2026	Common Stock	3,169	$0	0	D

Explanation of Responses:

1. The reporting person exercised the option due to the upcoming expiration date of the option.

2. All of the shares underlying this stock option vested on January 21, 2016.

	/s/ Shawn Glidden, attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Replimune Group, Inc. (REPL) report in this Form 4?

The filing shows a director of Replimune Group, Inc. exercised a stock option for 3,169 shares of common stock at $1.75 per share and then sold 3,169 shares at $10.4 per share on 12/09/2025.

How many Replimune (REPL) shares were sold and at what price?

The director sold 3,169 shares of Replimune common stock at a price of $10.4 per share on 12/09/2025, as reported in Table I with transaction code S.

What were the key terms of the Replimune (REPL) stock option that was exercised?

The derivative table reports a stock option (right to buy) covering 3,169 shares of common stock with an exercise price of $1.75 per share, an expiration date of 01/21/2026, and full vesting of all underlying shares on 01/21/2016.

What is the director's reported ownership in Replimune (REPL) after these transactions?

After the reported option exercise and sale, the director shows 0 shares of Replimune common stock beneficially owned in Table I and 0 derivative securities remaining from this option grant in Table II.

Why did the Replimune director exercise the stock option on 12/09/2025?

The explanation states that the director exercised the option due to the upcoming expiration date of the option, which was scheduled to expire on 01/21/2026.

Were the Replimune (REPL) option shares already vested at the time of exercise?

Yes. The disclosure notes that all of the shares underlying this stock option, totaling 3,169 shares, had vested on 01/21/2016.